The comparison of complications and costs between the administration of Omeprazole via IV push and IV infusion
Keywords:
Omeprazole administration via IV push and IV infusion, complications, costAbstract
This study was a randomized controlled trial aimed at comparing complications and treatment costs between intravenous (IV) push and IV infusion administration of omeprazole. The participants included 70 patients who received omeprazole either via IV push (35 patients) or IV infusion (35 patients) at Yi-ngo Community Hospital Commemorating His Majesty the King’s 80th Birthday Anniversary. The research instruments consisted of (1) guidelines for IV push and IV infusion administration of omeprazole, (2) a personal data recording form, (3) a treatment-related data recording form, (4) a complication recording form, and (5) a cost recording form related to omeprazole administration. The study was conducted from December 2024 to January 2025. Data were analyzed using descriptive statistics, including frequency distribution and percentage, as well as chi-square test, Fisher’s exact test, and independent t-test.
The results showed that the IV push group had a complication rate of 45.7%, whereas the IV infusion group had a complication rate of 28.6%. The most common complication was grade 2 phlebitis, which occurred more frequently in the IV push group. However, this difference in complication rates was not statistically significant (p = .142). No arrhythmias were observed in either group. Regarding treatment costs, the IV push group incurred a total cost of 2,250 baht (64.29 ± 37.52), while the IV infusion group had a significantly higher total cost of 4,393 baht (125.51 ± 90.75), with this difference being statistically significant (p = .001).
References
Lopes-de-Campos D, Pereira-Leite C, Fontaine P, Coutinho A, Prieto M, Sarmento B, Jakobtorweihen S, Nunes C, Reis S.(2021). Interface-Mediated Mechanism of Action-The Root of the Cytoprotective Effect of Immediate-Release Omeprazole. J Med Chem. 2021;64(8):5171-84.
Freedberg DE, Kim LS, Yang YX.(2017). The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152(4):706-15.
López-Velázquez G, Fernández-Lainez C, de la Mora-de la Mora JI, Caudillo de la Portilla D, Reynoso-Robles R, González-Maciel A, et al.(2019). On the molecular and cellular effects of omeprazole to further support its effectiveness as an antigiardial drug. Sci Rep. 2019;9(1):8922.
Hamzeloo-Moghadam M, Rezaei Tavirani M, Jahani-Sherafat S, Rezaei Tavirani S, Esmaeili S, Ansari M, Ahmadzadeh A.(2021). Side effects of omeprazole: a system biology study. Gastroenterol Hepatol Bed Bench. 2021;14(4):334-41.
Le Merdy M, Tan ML, Sun D, Ni Z, Lee SC, Babiskin A, et al.(2021). Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug-Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole. Eur J Drug Metab Pharmacokinet. 2021;46(1):41-51.
Cartee NMP, Wang MM.(2020). Binding of omeprazole to protein targets identified by monoclonal antibodies. PLoS One. 2020;15(9):e0239464.
Paz MFCJ, de Alencar MVOB, de Lima RMP, Sobral ALP, do Nascimento GTM, Dos Reis CA, et al.(2020). Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer. Oxid Med Cell Longev. 2020:3457890.
Al Ali HS, Jabbar AS, Neamah NF, Ibrahim NK.(2022). Long-Term Use of Omeprazole: Effect on Haematological and Biochemical Parameters. Acta Med Indones. 2022;54(4):585-94.
Guedes JVM, Aquino JA, Castro TLB, Augusto de Morais F, Baldoni AO, Belo VS, Otoni A.(2020). Omeprazole use and risk of chronic kidney disease evolution. PLoS One. 2020;15(3):e0229344.
Fontecha-Barriuso M, Martín-Sanchez D, Martinez-Moreno JM, Cardenas-Villacres D, Carrasco S, Sanchez-Niño MD, et al.(2020). Molecular pathways driving omeprazole nephrotoxicity. Redox Biol. 2020;32:101464.
Cerri S, Taminiau B, de Lusancay AH, Lecoq L, Amory H, Daube G, Cesarini C.(2020). Effect of oral administration of omeprazole on the microbiota of the gastric glandular mucosa and feces of healthy horses. J Vet Intern Med. 2020;34(6):2727-37.
Segregur D, Mann J, Moir A, Karlsson EM, Dressman J.(2021). Prediction of plasma profiles of a weakly basic drug after administration of omeprazole using PBPK modeling. Eur J Pharm Sci. 2021;158:105656.
Miedziaszczyk M, Idasiak-Piechocka I.(2023). Safety analysis of co-administering tacrolimus and omeprazole in renal transplant recipients - A review. Biomed Pharmacother. 2023;166:115149.
Taher KW, Yaseen R, Alnan M, Aburas W, Khalil H, Alabdulsalam M.(2024). Efficacy and safety of empiric treatment with omeprazole continuous infusion in critically ill children with gastrointestinal bleeding. Front Pediatr. 2024;12:1270911.
Pang SH, Graham DY.(2010). A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers. Therap Adv Gastroenterol. 2010;3(1):11-22.
American Society of Health-System Pharmacists (ASHP).(2020). ASHP injectable drug information 2020. Bethesda (MD): ASHP; 2020.
